ClinicalTrials.Veeva

Menu

Intra-articular Betamethasone and the Hypothalamic-pituitary-adrenal Axis

T

The Nazareth Hospital, Israel

Status

Completed

Conditions

Adrenal Suppression

Study type

Observational

Funder types

Other

Identifiers

NCT01799408
HPA-2012

Details and patient eligibility

About

To evaluate the effect of intra-articular corticosteroid injection (IACI) of depot preparation of betamethasone on the hypothalamic-pituitary-adrenal (HPA) axis, in patients with osteoarthritis of the knee

Full description

Consecutive patients attending the rheumatology or orthopedic clinic with osteoarthritic knee pain, not responding satisfactorily to medical or physical therapy were allocated to group-1 after consent and given IACI of 6 mg of betamethasone acetate/betamethasone sodium phosphate. Following completion of this part, consecutive age- and sex-matched patients were allocated to group-2 and given intra-articular injection of 60 mg of sodium hyaluronate. Just prior to the knee injection and 1, 2, 3, 4 and 8 weeks later, patients had 1 µg adrenocorticotropin hormone (ACTH) stimulation test. Secondary adrenal insufficiency (SAI) was defined as levels of less than 18 ng/ml or a rise of < than 7 ng/ml of serum cortisol, 30 minutes following the ACTH stimulation test.

Enrollment

40 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Osteoarthritis of the knee

Exclusion criteria

  • Had steroids in the last 3 months. Allergic to steroids

Trial design

40 participants in 2 patient groups

betamethasone
Description:
Patients who had intra-articular injection of betamethasone
Hyaluronic acid
Description:
Patients who had intra-articular injection of hyaluronic acid

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems